Read by QxMD icon Read

"Venture capital"

Lynn M Rose, Fiona Wills, Connie Bourassa-Shaw, Terri L Butler, Jeanette Griscavage Ennis, Kim Emmons, Patrick Shelby, Meher Antia, Kim Folger Bruce
Introduction: The Institute of Translational Health Sciences (ITHS), a Clinical and Translational Science Award (CTSA)-funded program at the University of Washington (UW), established the Drug and Device Advisory Committee (DDAC) to provide product-specific scientific and regulatory mentoring to investigators seeking to translate their discoveries into medical products. An 8-year retrospective analysis was undertaken to evaluate the impact of the DDAC programs on commercialization metrics...
August 2017: Journal of Clinical and Translational Science
Timothy Kelley
Some experts say that investors funding innovative startup companies can disrupt American health care, making it smarter and more efficient. Others warn that incentives must change if VC money is to make a real difference. It's a trend no one in health care can ignore.
November 2017: Managed Care
Timothy Kelley
This upbeat doctor-policymaker-entrepreneur sees opportunity where others see a federal policy train wreck these days. For instance, he's pleased that both political parties seem to endorse a shift from fee-for-service to value-based care. However, continuing uncertainty about the individual market may chill new investment in that area for a while.
August 2017: Managed Care
Juan-Pablo Mas, Brian Hsueh
Novel and transformative medical technologies of all forms have the potential to make a significant positive impact on the lives of patients and on the health care system, and one common pathway for guiding such innovations from concept through commercialization is via the formation of a company. For entrepreneurs looking to build a medical technology company, several common challenges await, including questions around how and where to raise funding. Here, we review key considerations for the formation of medical technology companies as viewed through the lens of an investor...
June 2017: Techniques in Vascular and Interventional Radiology
Thomas Kramps, Knut Elbers
RNA vaccines are attractive, because they exhibit characteristics of subunit vaccines and live-attenuated vectors, including flexible production and induction of both humoral and cellular immunity. While human proof-of-concept for RNA vaccines is still pending, the nascent field of RNA therapeutics has already attracted substantial industry and government funding as well as record investments of private venture capital. Most recently, the WHO acknowledged messenger RNA (mRNA) as a new therapeutic class. In this chapter, we briefly review key developments in RNA vaccines and outline the contents of this volume of Methods in Molecular Biology...
2017: Methods in Molecular Biology
Ting Cao
This article contains hand collected and matched data on the VC investment situation in newly listed firms in SME and ChiNext board from 2009 to 2012 and the corresponding M&A activities data undertaken by these newly listed firms as acquirers in three years following initial public offering. Mentioned data are related to the research article "Heterogeneous Venture Capital, M&A Activity, and Market Response" (W. Li, T. Cao, Z. Feng, 2016) [1].
December 2016: Data in Brief
P Lehoux, F A Miller, G Daudelin
While health policy scholars wish to encourage the creation of technologies that bring more value to healthcare, they may not fully understand the mandate of venture capitalists and how they operate. This paper aims to clarify how venture capital operates and to illustrate its influence over the kinds of technologies that make their way into healthcare systems. The paper draws on the international innovation policy scholarship and the lessons our research team learned throughout a 5-year fieldwork conducted in Quebec (Canada)...
July 2016: BMJ Innovations
Anne L J Ter Wal, Oliver Alexy, Jörn Block, Philipp G Sandner
Open networks give actors non-redundant information that is diverse, while closed networks offer redundant information that is easier to interpret. Integrating arguments about network structure and the similarity of actors' knowledge, we propose two types of network configurations that combine diversity and ease of interpretation. Closed-diverse networks offer diversity in actors' knowledge domains and shared third-party ties to help in interpreting that knowledge. In open-specialized networks, structural holes offer diversity, while shared interpretive schema and overlap between received information and actors' prior knowledge help in interpreting new information without the help of third parties...
September 2016: Administrative Science Quarterly
Mary Jo Potter, Rick Wesslund
As health systems continue to embrace disruptive innovation, they are increasingly likely to consider making a move into venture capital. Working in venture capital can benefit a health system in several ways, including: Allowing it to operate outside of bureaucracy and align projects with its core values. Encouraging innovation within the organization. Enabling it to respond quickly to changes in the market.
May 2016: Healthcare Financial Management: Journal of the Healthcare Financial Management Association
Bob Herman
No abstract text is available yet for this article.
March 21, 2016: Modern Healthcare
Marcus Holgersson, Tai Phan, Thomas Hedner
Startups fill an increasingly important role as innovators in the pharmaceutical industry, and patenting is typically central to their success. This article aims to explore patent management in pharmaceutical startups. The results show that startups need to deal with several challenges related to patenting and an 'entrepreneurial' approach to patent management is called for. Resource constraints, venture capital provision, exits and other conditions and events must be readily considered in the patent management process to build a successful pharmaceutical venture, something that could benefit the pharmaceutical industry as a whole...
July 2016: Drug Discovery Today
(no author information available yet)
The origins of PIQUR Therapeutics AG, which was established in 2011, are found in significant research work at the University of Basel. The main focus of the spin-off of the University of Basel is the active pharmaceutical ingredient PQR309, which was used for the first time at the beginning of 2014 in Phase I trials in humans at University Hospital Basel. The small molecule, which was developed for targeted cancer therapy, intervenes with two major signaling pathways of cell growth. In just three years PIQUR secured funding of over 37 million Swiss Francs from private investors and Versant Venture, a leading venture capital firm...
December 2014: Chimia
Markus Hosang
Innovation is one of the main driving factors for continuous and healthy economic growth and welfare. Switzerland as a resource-poor country is particularly dependent on innovation, and the life sciences, which comprise biotechnologies, (bio)pharmaceuticals, medical technologies and diagnostics, are one of the key areas of innovative strength of Switzerland. Venture capital financing and venture capitalists (frequently called 'VCs') and investors in public equities have played and still play a pivotal role in financing the Swiss biotechnology industry...
December 2014: Chimia
Pascal Gantenbein, Nils Herold
Despite its economic and technological importance, the Swiss life sciences sector faces severe challenges in attracting enough venture capital for its own development. Although biotechnology and medical technology have been the most important areas of venture financing from 1999 through 2012 according to our own data, average investment volumes nevertheless remain on a low level of only 0.05 percent of Swiss GDP. After 2008, there was a pronounced shift away from early-stage financing. While business angels still play an important role at the early stage, venture capitalists are the most important investor type by volumes having their main focus on expansion financing...
December 2014: Chimia
Yonghong Jin, Qi Zhang, Lifei Shan, Sai-Ping Li
Financial networks have been extensively studied as examples of real world complex networks. In this paper, we establish and study the network of venture capital (VC) firms in China. We compute and analyze the statistical properties of the network, including parameters such as degrees, mean lengths of the shortest paths, clustering coefficient and robustness. We further study the topology of the network and find that it has small-world behavior. A multiple linear regression model is introduced to study the relation between network parameters and major regional economic indices in China...
2015: PloS One
Pataje G S Prasanna, Deepa Narayanan, Kory Hallett, Eric J Bernhard, Mansoor M Ahmed, Gregory Evans, Bhadrasain Vikram, Michael Weingarten, C Norman Coleman
Although radiation therapy is an important cancer treatment modality, patients may experience adverse effects. The use of a radiation-effect modulator may help improve the outcome and health-related quality of life (HRQOL) of patients undergoing radiation therapy either by enhancing tumor cell killing or by protecting normal tissues. Historically, the successful translation of radiation-effect modulators to the clinic has been hindered due to the lack of focused collaboration between academia, pharmaceutical companies and the clinic, along with limited availability of support for such ventures...
September 2015: Radiation Research
Matthew S Bothner, Young-Kyu Kim, Wonjae Lee
We introduce a distinction between two kinds of status and examine their effects on the exit rates of organizations investing in the U.S. venture capital industry. Extending past work on status-based competition, we start with a simple baseline: we describe primary status as a network-related signal of an organization's quality in a leadership role, that is, as a function of the degree to which an organization leads others that are themselves well regarded as lead organizations in the context of investment syndicates...
July 2015: Social Science Research
Justine E Tinkler, Kjersten Bunker Whittington, Manwai C Ku, Andrea Rees Davies
Research on gender and workplace decision-making tends to address either supply-side disparities between men's and women's human and social capital, or demand-side differences in the status expectations of women and men workers. In addition, this work often relies on causal inferences drawn from empirical data collected on worker characteristics and their workplace outcomes. In this study, we demonstrate how tangible education and work history credentials - typically associated with supply-side characteristics - work in tandem with cultural beliefs about gender to influence the evaluative process that underlies venture capital decisions made in high-growth, high-tech entrepreneurship...
May 2015: Social Science Research
Jonathan J Fleming
A key element required for translating new knowledge into effective therapies is early-stage venture capital that finances the work needed to identify a lead molecule or medical device prototype and to develop it to the proof-of-concept stage. This early investment is distinguished by great uncertainty over whether the molecule or prototype is safe and effective, the stability of the regulatory standards to which clinical trials are designed, and the likelihood that large follow-on investments for commercial development can be secured...
February 2015: Health Affairs
Sabin Russell
No abstract text is available yet for this article.
February 2015: Health Affairs
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"